Asset profile
PDS0101 · PDS Biotechnology (PDSB)
- Indication
- HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma
- Also known as
- Versamune HPV
Company
PDSBPDS Biotechnology
PDSBPDS BiotechnologyPDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cance…
On the calendar
Timeline
Newest first.
Registered trials
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT04260126 | Phase 2 | Completed | May 14, 2025 | 95 | 18 of 23 sites in the United States |
| NCT05232851 | Phase 1/2 | Active, not recruiting | Apr 9, 2025 | 20 | 1 of 1 sites in the United States |
| NCT06790966 | Phase 3 | Terminated | Aug 25, 2026 | 12 | 28 of 28 sites in the United States |
| NCT04580771 | Phase 2 | Active, not recruiting | Mar 8, 2027 | 22 | 1 of 1 sites in the United States |
| NCT07090174 | Phase 2 | Withdrawn | Dec 31, 2026 | 0 | 2 of 3 sites in the United States |
More from PDS Biotechnology
Other drugs and candidates from the same company tracked in this sector.